Clinical trials: Left Ventricular Function
Dilated Cardiomyopathy, Heart Failure
PUFAs and Left Ventricular Function in Heart Failure
The purpose of this study is to test the hypothesis that n-3 PUFAs improve left ventricular systolic function in patients with stable chronic HF secondary to nonischemic dilated cardiomyopathy (NICM).
- Trial name
- CS-PUFA-02 (NCT01223703)
- Testing
- n-3 PUFAs
- Where
- Italy
- Volunteers
- 133 people
- Sponsor
- Università degli Studi di Brescia
Heart Failure
International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device
This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in…
- Trial name
- ADMIRE-ICD (NCT02656329)
- Testing
- Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
- Where
- 94 sites in United States, Canada and 8 more
- Volunteers
- 395 people
- Sponsor
- GE Healthcare
Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction
Ertugliflozin for Functional Mitral Regurgitation
In patients with heart failure (HF) and left ventricular (LV) dilation, adverse LV remodeling causes tethering of mitral valve (MV) preventing sufficient coaptation of normal leaflets and resulting in functional MR.
- Trial name
- EFFORT (NCT04231331)
- Testing
- Ertugliflozin
- Where
- 3 sites in South Korea
- Volunteers
- 128 people
- Sponsor
- Asan Medical Center
Heart Failure, Asymptomatic Systolic Dysfunction
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
The following are done for screening procedures to determine if patients are eligible for this study: blood count, kidney and liver blood tests. Patients will complete a 6-minute walk test.
- Trial name
- NCT00405639
- Testing
- Nesiritide
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Renal Dialysis, Hemodiafiltration
Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
Introduction: Cardiovascular disease is the leading cause of morbidity and mortality in patients undergoing hemodialysis, largely due to structural cardiac changes associated with left ventricular diastolic dysfunction.
- Conditions
- Renal Dialysis, Hemodiafiltration, Diastolic Dysfunction, Kidney Failure
- Trial name
- EXE-HDF (NCT06584734)
- Testing
- Not exercise, Exercise during hemodiafiltration session
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Impaired Glucose Tolerance
Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation
The purpose of the study is to examine the effect of saxagliptin, an anti-diabetes medication, on hepatic and myocardial fat content and monocyte inflammation in patients with Impaired Glucose Tolerance (IGT).
- Trial name
- NCT01548651
- Testing
- Saxagliptin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Baylor College of Medicine
Atrial Fibrillation, Heart Failure
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
- Trial name
- RAD HF (NCT01887353)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Intermountain Health Care, Inc.
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Dysfunction
PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
This study will be done in patients who require the implantation of a cardiac pacemaker (an electronic device that controls the heartbeat) for complete heart block (a heart rhythm abnormality resulting in a slow heart beat).
- Trial name
- PROTECT-PACE (NCT00461734)
- Testing
- RV lead placement site
- Where
- 18 sites in Australia, New Zealand and 1 more
- Volunteers
- 248 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypertension
Irbesartan and Atenolol in Hypertensive Heart Disease
The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure.
- Trial name
- SILVHIA (NCT00389168)
- Testing
- Irbesartan, Atenolol
- Where
- Sweden
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Permanent Atrial Fibrillation
Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Atrial fibrillation is a common heart rhythm disturbance, causing important discomfort for patients, a high risk of stroke, frequent hospital admissions and a two-fold increase in death.
- Trial name
- RATE-AF (NCT02391337)
- Testing
- Bisoprolol, Digoxin
- Where
- 2 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- University of Birmingham
Congestive Heart Failure
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
The purpose of this study is to determine if Coreg CR is as effective as Coreg IR in improving heart function in subjects with stable chronic heart failure.
- Trial name
- COMPARE (NCT00323037)
- Testing
- carvedilol controlled release, carvedilol immediate release
- Where
- 75 sites in United States
- Volunteers
- 318 people
- Sponsor
- CTI-1, LLC
Heart Failure
Effects of Echo-optimization of Left Ventricular Assist Devices on Functional Capacity (VAFRACT)
After the implantation of a left ventricular assist device (LVAD), many patients continue to experience exercise intolerance. LVAD echo guided optimization (EO) determines a more favorable hemodynamic profile and could provide an…
- Trial name
- VAFRACT (NCT03937570)
- Testing
- echo-optimization
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Universita di Verona